Shanghai Juntuo Biopharmaceutical Technology

Shanghai Juntuo Biopharmaceutical Technology is a clinical-stage biotechnology company focused on the development and commercialization of innovative therapies for infectious diseases and vaccines. As a subsidiary of Junshi Biosciences, the company has played a pivotal role in the global response to COVID-19 through the development of the oral antiviral VV116 and the neutralizing antibody Etesevimab. Their portfolio extends to next-generation vaccines and treatments for respiratory viruses and other high-burden pathogens. Juntuo leverages integrated R&D and manufacturing capabilities to accelerate the transition of candidates from discovery to market. The company is a key player in the Chinese biopharmaceutical landscape, particularly in the field of antiviral research.